Four decades. Billions spent.
Called "undruggable."

KRAS is mutated in 25% of all human cancers — pancreatic, lung, colorectal. For 40 years it was considered undruggable because the protein has no obvious binding pocket. Traditional drug discovery requires a cavity to lock into. LoNC doesn't require a cavity — it finds the physics of how molecules interact with the surface. Demo run ranked Switch-II pocket binders consistent with Sotorasib-class chemistry in minutes — throughput demo.

Keytruda. Oral.
No more infusion chairs.

PD-1/PD-L1 checkpoint inhibitors (Keytruda, Opdivo) are among the most transformative cancer drugs ever developed — and every patient receives them intravenously. The same LoNC platform computationally screened for oral small-molecule checkpoint inhibitor candidates — predictions only. Goal: oral alternatives to IV biologics — candidates require full preclinical and clinical validation.

One platform.
Every cancer mechanism.

Not one cancer.
The whole landscape.